• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC SOFAMOR DANEK USA, INC INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC SOFAMOR DANEK USA, INC INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Seroma (2069)
Event Date 12/01/2014
Event Type  Injury  
Event Description
It was reported in a publication that a total of 72 consecutive patients who were treated with a multi-level acdf using bcs and rhbmp-2 at a single institution between 2007 and 2012 were identified and included for analysis.Clinical outcomes and patient satisfaction were collected at preoperative and prospectively at 1, 3, 6, 12, and 24 months postoperative.All patients had initial x-rays within 24 hours of surgery, ap and lateral x-rays at 4 to 6 weeks postoperative, and serial x-rays with flexion and extension views at 3, 6, 12, and 24 months.Fusion was defined as a lack of instrumentation failure, no lucency in the intervertebral disc space, and no movement on flexion-extension radiographs.Mean follow-up of the 72 patients was 13.8 months (range 6-24 months).Primary clinical indication for surgery was classified as cervical spondylitic myelopathy (csm) in 29 (40%) patients, as radiculopathy (rad) in 27 (38%) patients, as a combination of csm and rad in 15 (21%) patients, and non-union in 1 (1%) patient.There were no cases of infection or wound problems, hematoma formation, or new postoperative neurologic deficit.Overall fusion was 98.6% of patients or 99.5% of treated levels.1 patient returned to the or for a retropharyngeal seroma evacuation.
 
Manufacturer Narrative
Article citation: khajavi et al in a publication entitled ¿safety and efficacy of bioabsorbable cervical spacers and low-dose rhbmp-2 in multi-level acdf¿ (int j spine surg.2014 dec 1;8:1-11.(b)(4).Neither the device nor films of applicable imaging studies were returned to the manufacturer for evaluation.Therefore, we are unable to determine the definitive cause of the reported event.Products from multiple manufacturers were implanted during the procedure.Although it is unknown if any of the devices contributed to the reported event, we are filing this mdr for notification purposes.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INFUSE BONE GRAFT
Type of Device
FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET
Manufacturer (Section D)
MEDTRONIC SOFAMOR DANEK USA, INC
4340 swinea rd
memphis TN 38118
Manufacturer (Section G)
MEDTRONIC SOFAMOR DANEK
1800 pyramid place
memphis TN 38132
Manufacturer Contact
huzefa mamoola
1800 pyramid place
memphis, TN 38132
9013963133
MDR Report Key4631695
MDR Text Key21724205
Report Number1030489-2015-00649
Device Sequence Number1
Product Code NEK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P000058
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 02/25/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 02/25/2015
Initial Date FDA Received03/25/2015
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age00055 YR
-
-